Development of Magnetic Resonance Spectroscopy (MRS) Biomarkers of Tumor Metabolism
N/A
18 Years
70 Years
18 Years
70 Years
Not Enrolling
Both
Glioma
Both
Glioma
Trial Information
Development of Magnetic Resonance Spectroscopy (MRS) Biomarkers of Tumor Metabolism
Inclusion Criteria:
- Male and female patients aged 18-70 years old with newly diagnosed operable glioma of
grade II or higher which is > 3cm in diameter based on radiographic examination
- Patients about to receive biopsy or resection of newly diagnosed glioma
Exclusion Criteria:
- Contraindication to magnetic resonance imaging (MRI): e.g. cardiac pacemaker,
metallic implants, known contrast allergy, and pregnancy
- Impaired renal function
- Current or previous chemotherapy, radiation, or other tumor treatment excluding
steroids
- Tumor location extra-cerebral, temporal, or in close proximity to frontal sinus
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
The test-retest repeatability of lactate and other metabolites when measured by multi-voxel MRSI in tumor tissue
Outcome Time Frame:
90 minutes
Safety Issue:
No
Principal Investigator
Medical Monitor
Investigator Role:
Study Director
Investigator Affiliation:
Merck
Authority:
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Study ID:
2010_027
NCT ID:
NCT01138813
Start Date:
March 2009
Completion Date:
February 2010
Related Keywords:
- Glioma
- magnetic resonance spectroscopy (MRS)
- lactate editing
- metabolite content
- glioma
- Glioma
Name | Location |
|---|
